Cornerstone Pharmaceuticals
Presencia
Rafael Holdings es una empresa que cotiza bajo el símbolo de cotización RFL (US).
Ejecutivos
Ver el organigrama con sus 12 ejecutivos principales
Biografías más buscadas en Cornerstone Pharmaceuticals
- Sanjeev Luther, President, Chief Executive Officer and Chairman of...
- Aaron Drillick, Director
- Joseph Stern, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Cornerstone Pharmaceuticals.
Farmacia
Rafael Holdings tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Cornerstone Pharmaceuticals
- UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
- Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer
- Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
- Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE
- Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.
- Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
- European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals’ CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer
- Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer NYSE:RFL
- Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) NYSE:RFL
- View more press releases Close
Redes sociales sobre Cornerstone Pharmaceuticals
- Cornerstone Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Cornerstone Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Sanjeev Luther 
Llame a Cornerstone Pharmaceuticals al +1 609...
